Table 1.
Satisfaction with fertility- and sexuality-related information in 319 young breast cancer survivors
| Total | Satisfied with FRI | Satisfied with SRI | |||
|---|---|---|---|---|---|
| Continuous data | Mean ± SD | Mean ± SD | P value | Mean ± SD | P value |
| Frequency data | n (% column) | n (% row) | n (% row) | ||
| At baseline (M0) | |||||
| Age, years | 36.7 ± 3.7 | 36.7 ± 3.7 | 0.658 | 36.7 ± 3.5 | 0.798 |
| French as mother-language | 0.615 | 0.901 | |||
| No | 17 (5.3) | 8 (47.1) | 7 (41.2) | ||
| Yes | 302 (94.7) | 161 (53.3) | 129 (42.7) | ||
| Living as a couple or having regular partner | 0.152 | 0.126 | |||
| No | 41 (12.9) | 26 (63.4) | 22 (53.7) | ||
| Yes | 278 (87.1) | 143 (51.4) | 114 (41.0) | ||
| Level of education | 0.977 | 0.086 | |||
| Lower than high school graduate | 103 (32.3) | 54 (52.4) | 53 (51.5) | ||
| High school graduate | 60 (18.8) | 31 (51.7) | 25 (41.7) | ||
| Greater than high school graduate | 137 (42.9) | 73 (53.3) | 51 (37.2) | ||
| Missing values | 19 (6.0) | ||||
| Employed | 0.251 | 0.050 | |||
| No | 55 (17.2) | 33 (60.0) | 30 (54.5) | ||
| Yes | 264 (82.8) | 136 (51.5) | 106 (40.2) | ||
| Having children | 0.446 | 0.911 | |||
| None | 50 (15.7) | 29 (58.0) | 21 (42.0) | ||
| One or more | 259 (81.2) | 135 (52.1) | 111 (42.9) | ||
| Missing values | 10 (3.1) | ||||
| Place of residence | 0.858 | 0.680 | |||
| Rural | 38 (11.9) | 21 (55.3) | 18 (47.4) | ||
| <200,000 inhabitants | 99 (31.0) | 54 (54.5) | 44 (44.4) | ||
| ≥200,000 inhabitants | 182 (57.1) | 94 (51.6) | 74 (40.7) | ||
| Had opportunity to ask questions at cancer disclosure | 0.002 | 0.041 | |||
| No | 56 (17.6) | 19 (33.9) | 17 (30.4) | ||
| Yes | 263 (82.4) | 150 (57.0) | 119 (45.2) | ||
| Received information about disease at cancer disclosure | 0.124 | 0.006 | |||
| No | 89 (27.9) | 41 (46.1) | 27 (30.3) | ||
| Yes | 230 (72.1) | 128 (55.7) | 109 (47.4) | ||
| Satisfied with information about disease at cancer disclosure | 0.035 | 0.004 | |||
| No | 123 (38.6) | 56 (45.5) | 40 (32.5) | ||
| Yes | 196 (61.4) | 113 (57.7) | 96 (49.0) | ||
| At 10 month after diagnosis (M10): medical characteristics | |||||
| Tumor stage | 0.960 | 0.349 | |||
| Stage 0 | 36 (11.3) | 19 (52.8) | 16 (44.4) | ||
| Stage I | 89 (27.9) | 47 (52.8) | 36 (40.4) | ||
| Stage II | 145 (45.5) | 79 (54.5) | 63 (43.4) | ||
| Stage III | 44 (13.8) | 22 (50.0) | 21 (47.7) | ||
| Unknown | 5 (1.6) | 2 (40.0) | 0 (0.0) | ||
| Breast surgery | 0.216 | 0.250 | |||
| Mastectomy | 121 (37.9) | 59 (48.8) | 57 (47.1) | ||
| Tumorectomy | 195 (61.1) | 109 (55.9) | 71 (40.5) | ||
| Missing values | 3 (0.9) | ||||
| Chemotherapy | 0.769 | 0.752 | |||
| No | 70 (21.9) | 36 (51.4) | 31 (44.3) | ||
| Yes | 249 (78.1) | 133 (53.4) | 105 (42.2) | ||
| FEC100 chemotherapy regimen | 0.126 | 0.430 | |||
| No | 142 (44.5) | 82 (57.7) | 64 (45.1) | ||
| Yes | 177 (55.5) | 87 (49.2) | 72 (40.7) | ||
| Radiotherapy | 0.696 | 0.206 | |||
| No | 32 (10.0) | 18 (56.3) | 17 (53.1) | ||
| Yes | 287 (90.0) | 151 (52.6) | 119 (41.5) | ||
| Trastuzumab treatment | 0.728 | 0.185 | |||
| No | 259 (81.2) | 136 (52.5) | 115 (44.4) | ||
| Yes | 60 (18.8) | 33 (55.0) | 21 (35.0) | ||
| Hormone treatment | 0.197 | 0.094 | |||
| No | 120 (37.6) | 58 (48.3) | 44 (36.7) | ||
| Yes | 199 (62.4) | 111 (55.8) | 92 (46.2) | ||
| Family history of breast or ovarian cancer | 0.076 | 0.468 | |||
| No | 225 (70.5) | 112 (49.8) | 93 (41.3) | ||
| Yes | 94 (29.5) | 57 (60.6) | 43 (45.7) | ||
| Report of “serious” comorbiditiesa by physician | 0.401 | 0.441 | |||
| No | 273 (85.6) | 142 (52.0) | 114 (41.8) | ||
| Yes | 46 (14.4) | 27 (58.7) | 22 (47.8) | ||
| At 10 month after diagnosis (M10): patient questionnaire | |||||
| Attention and⁄or memory problems | 0.232 | 0.037 | |||
| No | 99 (31.0) | 57 (57.6) | 51 (51.5) | ||
| Yes | 201 (63.0) | 101 (50.2) | 78 (38.8) | ||
| Missing values | 19 (6.0) | ||||
| MAC-21 score | |||||
| Anxious preoccupation subscale | 50.0 ± 10.0 | 48.3 ± 10.3 | 0.001 | 48.8 ± 10.4 | 0.084 |
| Fighting spirit subscale | 50.6 ± 10.0 | 51.9 ± 9.1 | 0.014 | 51.4 ± 9.0 | 0.196 |
| Hopelessness/helplessness subscale | 49.2 ± 9.6 | 48.3 ± 8.6 | 0.075 | 49.1 ± 8.6 | 0.784 |
| At 48 month after diagnosis (M48) | |||||
| Preserved fertility | 0.478 | 0.429 | |||
| No | 221 (69.3) | 120 (54.3) | 91 (41.2) | ||
| Yes | 98 (30.7) | 49 (50.0) | 45 (45.9) | ||
| Satisfied with medical follow-up | 0.005 | 0.007 | |||
| No | 91 (28.5) | 37 (40.7) | 28 (30.8) | ||
| Yes | 228 (71.5) | 132 (57.9) | 108 (47.4) | ||
| Score of sexual dysfunction (RSS subscale) | 9.5 ± 4.1 | 9.2 ± 4.2 | 0.113 | 9.1 ± 4.2 | 0.110 |
FRI fertility-related information; SRI sexuality-related information; SD standard deviation; MAC-21 21-item mental adjustment scale to cancer; RSS relationship and sexuality scale
aIncluding asthma, diabetes, cardiac problems, HIV infection and/or Hodgkin’s disease